Ontology highlight
ABSTRACT:
SUBMITTER: Ravandi F
PROVIDER: S-EPMC2930809 | biostudies-literature | 2010 Apr
REPOSITORIES: biostudies-literature
Ravandi Farhad F Cortes Jorge E JE Jones Daniel D Faderl Stefan S Garcia-Manero Guillermo G Konopleva Marina Y MY O'Brien Susan S Estrov Zeev Z Borthakur Gautam G Thomas Deborah D Pierce Sherry R SR Brandt Mark M Byrd Anna A Bekele B Nebiyou BN Pratz Keith K Luthra Rajyalakshmi R Levis Mark M Andreeff Michael M Kantarjian Hagop M HM
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100308 11
PURPOSE To determine the efficacy and toxicity of the combination of sorafenib, cytarabine, and idarubicin in patients with acute myeloid leukemia (AML) younger than age 65 years. PATIENTS AND METHODS In the phase I part of the study, 10 patients with relapsed AML were treated with escalating doses of sorafenib with chemotherapy to establish the feasibility of the combination. We then treated 51 patients (median age, 53 years; range, 18 to 65 years) who had previously untreated AML with cytarabi ...[more]